Sztul E S, Hendrick J P, Kraus J P, Wall D, Kalousek F, Rosenberg L E
Department of Human Genetics, Yale University School of Medicine, New Haven, Connecticut 06510.
J Cell Biol. 1987 Dec;105(6 Pt 1):2631-9. doi: 10.1083/jcb.105.6.2631.
The mitochondrial matrix enzyme ornithine transcarbamylase (OTC) is synthesized on cytoplasmic polyribosomes as a precursor (pOTC) with an NH2-terminal extension of 32 amino acids. We report here that rat pOTC synthesized in vitro is internalized and cleaved by isolated rat liver mitochondria in two, temporally separate steps. In the first step, which is dependent upon an intact mitochondrial membrane potential, pOTC is translocated into mitochondria and cleaved by a matrix protease to a product designated iOTC, intermediate in size between pOTC and mature OTC. This product is in a trypsin-protected mitochondrial location. The same intermediate-sized OTC is produced in vivo in frog oocytes injected with in vitro-synthesized pOTC. The proteolytic processing of pOTC to iOTC involves the removal of 24 amino acids from the NH2 terminus of the precursor and utilizes a cleavage site two residues away from a critical arginine residue at position 23. In a second cleavage step, also catalyzed by a matrix protease, iOTC is converted to mature OTC by removal of the remaining eight residues of leader sequence. To define the critical regions in the OTC leader peptide required for these events, we have synthesized OTC precursors with alterations in the leader. Substitution of either an acidic (aspartate) or a "helix-breaking" (glycine) amino acid residue for arginine 23 of the leader inhibits formation of both iOTC and OTC, without affecting translocation. These mutant precursors are cleaved at an otherwise cryptic cleavage site between residues 16 and 17 of the leader. Interestingly, this cleavage occurs at a site two residues away from an arginine at position 15. The data indicate that conversion of pOTC to mature OTC proceeds via the formation of a third discrete species: an intermediate-sized OTC. The data suggest further that, in the rat pOTC leader, the essential elements required for translocation differ from those necessary for correct cleavage to either iOTC or mature OTC.
线粒体基质酶鸟氨酸转氨甲酰酶(OTC)在细胞质多核糖体上以前体形式(pOTC)合成,其氨基末端有32个氨基酸的延伸序列。我们在此报告,体外合成的大鼠pOTC被分离的大鼠肝线粒体摄取并在两个时间上分开的步骤中被切割。第一步依赖于完整的线粒体膜电位,pOTC被转运到线粒体中,并被基质蛋白酶切割成一种称为iOTC的产物,其大小介于pOTC和成熟OTC之间。该产物位于胰蛋白酶保护的线粒体位置。在注射了体外合成的pOTC的蛙卵母细胞中,体内也产生了相同大小的中间型OTC。pOTC到iOTC的蛋白水解加工涉及从前体的氨基末端去除24个氨基酸,并利用一个距第23位关键精氨酸残基两个残基的切割位点。在第二步切割中,同样由基质蛋白酶催化,iOTC通过去除前导序列的其余8个残基转化为成熟OTC。为了确定这些事件所需的OTC前导肽中的关键区域,我们合成了前导序列有改变的OTC前体。用酸性(天冬氨酸)或“螺旋破坏”(甘氨酸)氨基酸残基替代前导序列的第23位精氨酸,会抑制iOTC和OTC的形成,但不影响转运。这些突变前体在位于前导序列第16和17位残基之间的一个原本隐蔽的切割位点处被切割。有趣的是,这种切割发生在距第15位精氨酸两个残基的位点处。数据表明,pOTC向成熟OTC的转化通过形成第三种离散形式进行:一种中间大小的OTC。数据进一步表明,在大鼠pOTC前导序列中,转运所需的基本元件与正确切割成iOTC或成熟OTC所需的元件不同。